• Werewolf Therapeutics will present cancer studies at the Society for Immunotherapy of Cancer meeting, November 4-8, 2026, in Phoenix.
• A November 7 oral presentation will cover Phase 1/1b testing of WTX-124 alone or with pembrolizumab in advanced solid tumors.
• A poster that day will feature the Phase 1b/2 study of WTX-330 in patients with relapsed or refractory solid tumors.
• Both experimental treatments are designed to activate selectively within tumors to stimulate immune responses against cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300830PRIMZONEFULLFEED9856460) on October 30, 2026, and is solely responsible for the information contained therein.